Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on BSX stock, giving a Buy rating yesterday.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Anthony Petrone’s rating is based on Boston Scientific’s strong financial performance and promising growth prospects. The company exceeded expectations with a significant revenue beat, driven by the rapid adoption of the FaraPulse technology in the U.S. and a rebound in WATCHMAN FLX procedures. These factors contributed to an impressive organic growth rate, particularly in the Cardiovascular segment, significantly surpassing market predictions.
Furthermore, the company demonstrated strong profitability with improvements in operating margins and adjusted earnings per share. The initial guidance for the following year also shows optimism, with growth forecasts exceeding Street expectations, supported by continued momentum in key product lines. This combination of robust current performance and favorable future outlook underpins Petrone’s positive recommendation for the stock.
In another report released yesterday, TD Cowen also reiterated a Buy rating on the stock with a $115.00 price target.
Based on the recent corporate insider activity of 131 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BSX in relation to earlier this year.